A. Bryskier
Impact in
- Molecular Medicine top 0.5%
- Antibiotic Resistance in Bacteria
- Pharmacology top 1%
- Antibiotics Pharmacokinetics and Efficacy
Papers in
-
- Antibiotic Resistance in Bacteria 49
- Co-authors
- Jean‐François ChantotNalin RastogiRalf René ReinertKhye Seng GohRudolf LüttickenM. T. LabroRenaud CholletH Drugeon
- Journals
- Antimicrobial Agents and Chemotherapy (31 papers)Journal of Antimicrobial Chemotherapy (13 papers)Expert Opinion on Investigational Drugs (11 papers)Clinical Microbiology and Infection (8 papers)Clinical Infectious Diseases (3 papers)
- Partner nations
- FranceUnited StatesGermany
In The Last Decade
A. Bryskier
110 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 110
- Molecular Medicine 730
- Pharmacology 809
- Infectious Diseases 796
- Microbiology 221
- Applied Microbiology and Biotechnology 70
Countries citing papers authored by A. Bryskier
This map shows the geographic impact of A. Bryskier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bryskier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bryskier more than expected).
Fields of papers citing papers by A. Bryskier
This network shows the impact of papers produced by A. Bryskier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bryskier. The network helps show where A. Bryskier may publish in the future.
Co-authorship network
The 25 scholars most cited alongside A. Bryskier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Antimicrobial agents: antibacterials and antifungals. | 2005 | 138 |
| 2 | 2005 | 4 | |
| 3 | 2005 | 10 | |
| 4 | 2004 | 6 | |
| 5 | 2000 | 62 | |
| 6 | 2000 | 37 | |
| 7 | 1999 | 9 | |
| 8 | 1999 | 14 | |
| 9 | Historique, classifications et perspectives de développement des antibiotiques et des agents antibactériens | 1997 | 1 |
| 10 | 1997 | 18 | |
| 11 | 1997 | 10 | |
| 12 | 1997 | 1 | |
| 13 | Effect of RU004 on oxidant production by human neutrophils | 1996 | 2 |
| 14 | 1995 | 97 | |
| 15 | 1990 | 6 | |
| 16 | 1990 | 17 | |
| 17 | 1990 | 13 | |
| 18 | [In vitro activity of roxithromycin, new semisynthetic macrolide against obligate anaerobes]. | 1986 | 3 |
| 19 | 1986 | 2 | |
| 20 | 1985 | 7 |
About A. Bryskier
A. Bryskier is a scholar working on Molecular Medicine, Applied Microbiology and Biotechnology, Pharmacology, Infectious Diseases and Microbiology, having authored 121 papers that have together received 2.4k indexed citations. Recurring topics across this work include Antibiotics Pharmacokinetics and Efficacy (57 papers), Antibiotic Resistance in Bacteria (49 papers), Pneumonia and Respiratory Infections (30 papers), Antimicrobial Resistance in Staphylococcus (13 papers), Cancer therapeutics and mechanisms (13 papers), Tuberculosis Research and Epidemiology (12 papers), Pneumocystis jirovecii pneumonia detection and treatment (10 papers) and Mycobacterium research and diagnosis (10 papers). The work is most often cited by research in Molecular Medicine (730 citations), Pharmacology (809 citations), Infectious Diseases (796 citations), Microbiology (221 citations) and Applied Microbiology and Biotechnology (70 citations). A. Bryskier has collaborated with scholars based in France, United States and Germany. Frequent co-authors include Jean‐François Chantot, Nalin Rastogi, Ralf René Reinert, Khye Seng Goh, Rudolf Lütticken, M. T. Labro, Renaud Chollet, H Drugeon, Jacqueline Chevalier and Adnan Al‐Lahham. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy, Expert Opinion on Investigational Drugs, Clinical Microbiology and Infection and Clinical Infectious Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.